Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
United Therapeutics (UTHR)
NASDAQ:UTHR
United Therapeutics (UTHR) Stock Price & Analysis
436 Followers
UTHR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$204.44 - $261.54
Previous Close$243.27
Volume1.11M
Average Volume (3M)406.57K
Market Cap
$11.45B
Enterprise Value$9.15B
Total Cash (Recent Filing)$2.99B
Total Debt (Recent Filing)$700.00M
Price to Earnings (P/E)12.3
Beta0.54
Next Earnings
May 01, 2024EPS Estimate
$5.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)19.84
Shares Outstanding47,058,545
10 Day Avg. Volume526,926
30 Day Avg. Volume406,569
Standard Deviation0.10
R-Squared0.07
Alpha0.00878
Financial Highlights & Ratios
Price to Book (P/B)1.99
Price to Sales (P/S)18.62
Price to Cash Flow (P/CF)19.40
P/FCF Ratio35.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.93
Enterprise Value/Gross Profit4.42
Enterprise Value/Ebitda6.74
Forecast
1Y Price Target
$290.00Price Target Upside26.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
United Therapeutics News
PremiumCompany Announcements
United Therapeutics Announces $1 Billion Stock Buyback Plan
PremiumCompany Announcements
United Therapeutics Sues FDA Over Liquidia’s Drug ExpansionOwnership Overview
11.46% Insiders
26.87% Mutual Funds
49.28% Other Institutional Investors
12.39% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
UTHR FAQ
What was United Therapeutics’s price range in the past 12 months?
United Therapeutics lowest stock price was $204.44 and its highest was $261.54 in the past 12 months.
What is United Therapeutics’s market cap?
Currently, no data Available
When is United Therapeutics’s upcoming earnings report date?
United Therapeutics’s upcoming earnings report date is May 01, 2024 which is in 13 days.
How were United Therapeutics’s earnings last quarter?
United Therapeutics released its earnings results on Feb 21, 2024. The company reported $4.36 earnings per share for the quarter, beating the consensus estimate of $4.284 by $0.076.
Is United Therapeutics overvalued?
According to Wall Street analysts United Therapeutics’s price is currently Undervalued.
Does United Therapeutics pay dividends?
United Therapeutics does not currently pay dividends.
What is United Therapeutics’s EPS estimate?
United Therapeutics’s EPS estimate is $5.79.
How many shares outstanding does United Therapeutics have?
United Therapeutics has 47,058,544 shares outstanding.
What happened to United Therapeutics’s price movement after its last earnings report?
United Therapeutics reported an EPS of $4.36 in its last earnings report, beating expectations of $4.284. Following the earnings report the stock price went up 2.344%.
Which hedge fund is a major shareholder of United Therapeutics?
Among the largest hedge funds holding United Therapeutics’s share is Farallon Capital Management, L.L.C.. It holds United Therapeutics’s shares valued at 105M.
---
United Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$290.00 (26.24% Upside)
$290.00 (26.24% Upside)
Blogger Sentiment
Bullish
UTHR Sentiment 88%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 364.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.9%
Last 30 Days ▲ 26.7%
Last 30 Days ▲ 26.7%
News Sentiment
Very Bullish
Bullish news 88%
Bearish news 13%
Bearish news 13%
Technicals
SMA
Positive
20 days / 200 days
Momentum
4.93%
12-Months-Change
Fundamentals
Return on Equity
18.27%
Trailing 12-Months
Asset Growth
18.47%
Trailing 12-Months
Company Description
United Therapeutics
United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. The firm also involves in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.
---
UTHR Earnings Call
Q4 2024
0:00 / 0:00
---
UTHR Stock 12 Months Forecast
Average Price Target
$290.00
▲(26.24% Upside)
Technical Analysis
Best Analysts Covering UTHR
1 Year
1 Year Success Rate
24/28 ratings generated profit
1 Year Average Return
+18.82%
reiterated a buy rating 3 months ago
Copying Eun Yang's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +18.82% per trade.
---